R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation

Perrigo vs MannKind: A Decade of R&D Investment

__timestampMannKind CorporationPerrigo Company plc
Wednesday, January 1, 2014100244000152500000
Thursday, January 1, 201529674000187800000
Friday, January 1, 201614917000184000000
Sunday, January 1, 201714118000167700000
Monday, January 1, 20188737000218600000
Tuesday, January 1, 20196900000187400000
Wednesday, January 1, 20206248000177700000
Friday, January 1, 202112312000122000000
Saturday, January 1, 202219721000123100000
Sunday, January 1, 202331283000122500000
Loading chart...

Data in motion

R&D Investment Trends: A Decade in Review

In the competitive landscape of pharmaceutical innovation, research and development (R&D) spending is a critical indicator of a company's commitment to future growth. Over the past decade, Perrigo Company plc and MannKind Corporation have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Perrigo consistently outspent MannKind, with its R&D expenses peaking in 2018 at nearly 2.2 times MannKind's highest expenditure in 2014. Despite a 70% reduction in MannKind's R&D spending from 2014 to 2019, the company has shown a resurgence, increasing its investment by over 400% from 2019 to 2023. Meanwhile, Perrigo's R&D spending has remained relatively stable, with a slight decline of around 20% from its 2018 peak. This analysis highlights the dynamic nature of R&D strategies in the pharmaceutical sector, reflecting each company's unique approach to innovation and market adaptation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025